Jennison Health Sciences Z
Gateway Center Three, 4th Floor 100 Mulberry Street Newark NJ 07102
Phone: 800-225-1852
| Category: |
Specialty-Health |
| Fund Family: |
JennisonDryden |
| Net Assets: |
357.09M |
| Year-to-Date Return: |
17.28% |
| Yield: |
0.00% |
| Morningstar Rating: |
 |
| Fund Inception Date: |
30-Jun-99 |
|
David Chan
Lead Manager since
30-Jun-99 |
|
| Chan joined Jennison Associates in 1992 and is a director and senior vice president. Previously, he was employed at Boston Consulting Group where he was a team leader and consultant on projects in many industries, including pharmaceuticals and drug retailing and distribution. Chan holds the Chartered Financial Analyst designation. |
| Min Initial Investment: |
$0 |
| Min Initial Investment, IRA: |
$0 |
| Min Initial Investment, AIP: |
$50 |
| Min Subsequent Investment: |
$0 |
| Min Subsequent Investment, IRA: |
$0 |
| Min Subsequent Investment, AIP: |
$50 |
|
|
|
| The investment seeks long-term capital appreciation. The fund normally invests at least 80% of investable assets in equity and equity-related securities of companies in the banking and financial services group of industries. It may invest more than 5% of assets in any one issuer. The fund may invest in ADRs and S&P Depositary Receipts, REITs, warrants and rights. It may participate in the IPO market. The fund may also invest up to 35% of total assets in foreign securities (excluding ADRs, ADSs, or similar receipts and shares traded in U.S. markets). It is nondiversified. |
| Last Dividend
(27-Nov-06):
|
0.00 |
| Last Cap Gain
(12-Dec-07):
|
2.12 |
| Annual Holdings Turnover
|
103.00% |
| Average for Category:
|
111.27% |
|
| Expense |
PHSZX |
Category
Avg |
| Total Expense Ratio: |
0.94%
|
1.71% |
| Max 12b1 Fee: |
0.00%
|
N/A |
| Max Front End Sales Load: |
0.00%
|
5.29% |
| Max Deferred Sales Load: |
0.00%
|
2.95% |
| 3 Yr Expense Projection*: |
$300 |
$723 |
| 5 Yr Expense Projection*: |
$520 |
$1,095 |
| 10 Yr Expense Projection*: |
$1,155 |
$2,134 |
|
|
Help
0.14 (0.70%) 
Profile
